| Q64112102 | A cmap-enabled gene expression signature-matching approach identifies small-molecule inducers of accelerated cell senescence |
| Q58769223 | A novel cell-based screening assay for small-molecule MYB inhibitors identifies podophyllotoxins teniposide and etoposide as inhibitors of MYB activity |
| Q43689095 | A novel topoisomerase II poison GL331 preferentially induces DNA cleavage at (C/G)T sites and can cause telomere DNA damage |
| Q36268156 | Abacavir, an anti-HIV-1 drug, targets TDP1-deficient adult T cell leukemia |
| Q33513762 | Accurate molecular classification of cancer using simple rules |
| Q91891315 | Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models |
| Q34661832 | Acute lymphoblastic leukemia: optimizing treatment strategies in children |
| Q41200355 | Acute nonlymphocytic leukemia following chemotherapy with cisplatin and etoposide for non-small-cell carcinoma of the lung: case report |
| Q34183849 | Adipose-derived stem cells retain their regenerative potential after methotrexate treatment. |
| Q28487763 | Amitozyn impairs chromosome segregation and induces apoptosis via mitotic checkpoint activation |
| Q35788447 | Amsacrine as a topoisomerase II poison: importance of drug-DNA interactions |
| Q36431000 | Anti-tumour activities of a new benzo[c]phenanthridine agent, 2,3-(methylenedioxy)-5-methyl-7-hydroxy-8-methoxybenzo[c]phena nthridini um hydrogensulphate dihydrate (NK109), against several drug-resistant human tumour cell lines |
| Q37932369 | Antineoplastic drugs in 1990. A review (Part II). |
| Q36074267 | Antitumor agents 294. Novel E-ring-modified camptothecin-4β-anilino-4'-O-demethyl-epipodophyllotoxin conjugates as DNA topoisomerase I inhibitors and cytotoxic agents |
| Q72959719 | Antitumor agents. 125. New 4 beta-benzoylamino derivatives of 4'-O-demethyl-4-desoxypodophyllotoxin and 4 beta-benzoyl derivatives of 4'-O-demethylpodophyllotoxin as potent inhibitors of human DNA topoisomerase II |
| Q72962841 | Antitumor agents. 126. Novel 4 beta-substituted anilino derivatives of 3',4'-O,O-didemethylpodophyllotoxin as potent inhibitors of human DNA topoisomerase II |
| Q67914971 | Antitumor drug cross-resistance in vivo in a cisplatin-resistant murine P388 leukemia |
| Q54158839 | Biomodulation by hyperthermia of topoisomerase II-targeting drugs in human colorectal cancer cells. |
| Q34545133 | Cancer chemotherapy: new strategies for success |
| Q34379629 | Catalytic core of human topoisomerase IIα: insights into enzyme-DNA interactions and drug mechanism |
| Q36465770 | Characterisation of VP-16-induced DNA cleavage in oestrogen-stimulated human breast cancer cells |
| Q37324752 | Characterization and interlaboratory comparison of a gene expression signature for differentiating genotoxic mechanisms |
| Q28327002 | Characterization of DNA topoisomerase I from Candida albicans as a target for drug discovery |
| Q41619991 | Characterization of camptothecin-resistant chinese hamster lung cells |
| Q41134704 | Chromosomes with two intact axial cores are induced by G2 checkpoint override: evidence that DNA decatenation is not required to template the chromosome structure |
| Q72314335 | Chronic oral etoposide in advanced breast cancer |
| Q36136151 | Cisplatin and etoposide in oesophageal cancer: a phase II study. Rotterdam Oesophageal Tumour Study Group |
| Q64387165 | Comparison of the effect of three different topoisomerase II inhibitors combined with cisplatin in human glioblastoma cells sensitized with double strand break repair inhibitors |
| Q44045668 | Cytotoxic properties of a new synthetic demethylpodophyllotoxin derivative, BN 58705, against human tumor cell lines |
| Q41888583 | DNA damage response to the Mdm2 inhibitor nutlin-3. |
| Q40818137 | DNA topoisomerase II activity in nonreplicating, transcriptionally inactive, chicken late spermatids |
| Q39498218 | DNA topoisomerase II as a target of antineoplastic drug therapy |
| Q42572866 | DNA topoisomerase II cleaves at specific sites in the 5' flanking region of c-fos proto-oncogenes in vitro |
| Q36758354 | DNA topoisomerases from pathogenic fungi: targets for the discovery of antifungal drugs |
| Q39016546 | Design, synthesis, and biological evaluation of a novel series of bisintercalating DNA-binding piperazine-linked bisanthrapyrazole compounds as anticancer agents |
| Q37574005 | Differential and common DNA repair pathways for topoisomerase I- and II-targeted drugs in a genetic DT40 repair cell screen panel |
| Q42011317 | Differential protective effects of varying degrees of hypoxia on the cytotoxicities of etoposide and bleomycin |
| Q36235740 | Dissociation of centrosome replication events from cycles of DNA synthesis and mitotic division in hydroxyurea-arrested Chinese hamster ovary cells |
| Q60301633 | Drug discovery of anticancer drugs targeting methylenetetrahydrofolate dehydrogenase 2 |
| Q42314511 | Dual effectiveness of Alternaria but not Fusarium mycotoxins against human topoisomerase II and bacterial gyrase |
| Q33433190 | Effective reinduction therapy for childhood acute nonlymphoid leukemia using simultaneous continuous infusions of teniposide and amsacrine |
| Q35679872 | Effects of Olive Metabolites on DNA Cleavage Mediated by Human Type II Topoisomerases |
| Q40566269 | Effects of VM26 (teniposide), a specific inhibitor of type II DNA topoisomerase, on SV40 DNA replication in vivo |
| Q37383911 | Effects of magnesium and related divalent metal ions in topoisomerase structure and function. |
| Q40391028 | Effects of the antitumor drug VP16 (etoposide) on the archaebacterial Halobacterium GRB 1.7 kb plasmid in vivo |
| Q36153748 | Efficacy of oral Etoposide in pretreated metastatic breast cancer: a multicenter phase 2 study |
| Q53606338 | Emetic potential of daily oral etoposide. |
| Q40694385 | Epipodophyllotoxins in the treatment of childhood cancer |
| Q35822033 | Epipodophyllotoxins, alkylating agents, and radiation and risk of secondary leukaemia after childhood cancer |
| Q45105697 | Establishment and characterization of resistant cells to etoposide (VP16) from a mouse breast cancer cell line, FM3A. |
| Q37601249 | Etoposide (VP-16-213)-induced gene alterations: potential contribution to cell death |
| Q37922821 | Etoposide and teniposide in the treatment of acute leukemia |
| Q39523026 | Etoposide and teniposide. Bioanalysis, metabolism and clinical pharmacokinetics |
| Q35435861 | Etoposide sensitizes CT26 colorectal adenocarcinoma to radiation therapy in BALB/c mice |
| Q41332538 | Etoposide-induced DNA cleavage in human leukemia cells |
| Q37917105 | Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer |
| Q61798290 | Evaluation of site-specific homologous recombination activity of BRCA1 by direct quantitation of gene editing efficiency |
| Q40789828 | Expression of drug resistance genes in VP-16 and mAMSA-selected human carcinoma cells |
| Q46331807 | Expressions of resistance and cross-resistance in teniposide-resistant L1210 cells |
| Q48373870 | Human autopsy tissue distribution of the epipodophyllotoxins etoposide and teniposide |
| Q37271887 | Identification of genomic regions contributing to etoposide-induced cytotoxicity |
| Q36911574 | In vivo localization of DNA topoisomerase II cleavage sites on Drosophila heat shock chromatin |
| Q39870942 | Induction of calf thymus topoisomerase II-mediated DNA breakage by the antibacterial isothiazoloquinolones A-65281 and A-65282 |
| Q34909651 | Interactions between the etoposide derivative F14512 and human type II topoisomerases: implications for the C4 spermine moiety in promoting enzyme-mediated DNA cleavage |
| Q36379849 | Interlinked DNA nano-circles for measuring topoisomerase II activity at the level of single decatenation events |
| Q40757795 | Modification of the 8 drugs in 1 day regimen: feasibility of substitution of other agents. |
| Q42407872 | Modulation of therapy-induced senescence by reactive lipid aldehydes |
| Q34051008 | Mutational analysis of a type II topoisomerase cleavage site: distinct requirements for enzyme and inhibitors |
| Q41571202 | Novel selection and genetic characterisation of an etoposide-resistant human leukaemic CCRF-CEM cell line |
| Q34572663 | Novobiocin enhances alkylating agent cytotoxicity and DNA interstrand crosslinks in a murine model |
| Q99711909 | Oxygen-Free Regioselective Biocatalytic Demethylation of Methyl-phenyl Ethers via Methyltransfer Employing Veratrol-O-demethylase |
| Q33919425 | Periodicity of DNA folding in higher order chromatin structures |
| Q39768346 | Pharmacokinetics of anticancer drugs in children |
| Q54303722 | Pharmacokinetics of continuous-infusion amsacrine and teniposide for the treatment of relapsed childhood acute nonlymphocytic leukemia. |
| Q37658182 | Phytochemicals as Anticancer and Chemopreventive Topoisomerase II Poisons |
| Q56334908 | Polyamine-containing etoposide derivatives as poisons of human type II topoisomerases: Differential effects on topoisomerase IIα and IIβ |
| Q41650634 | Potentiation of etoposide-induced cytotoxicity and DNA damage in CCRF-CEM cells by pretreatment with non-cytotoxic concentrations of arabinosyl cytosine |
| Q39378487 | Proteomic investigations reveal a role for RNA processing factor THRAP3 in the DNA damage response |
| Q48326443 | Quantification of Etoposide Hypersensitivity: A Sensitive, Functional Method for Assessing Pluripotent Stem Cell Quality. |
| Q64902788 | Recent developments in topoisomerase-targeted cancer chemotherapy. |
| Q27005726 | Recent progress on C-4-modified podophyllotoxin analogs as potent antitumor agents |
| Q37394291 | Role for topoisomerases in the release of DNA into the detergent-soluble fraction of eukaryotic cells |
| Q41873946 | Role of the semi-quinone free radical of the anti-tumour agent etoposide (VP-16-213) in the inactivation of single- and double-stranded phi X174 DNA. |
| Q33929257 | Sequence specificity of DNA topoisomerase I in the presence and absence of camptothecin |
| Q41500551 | Structure-activity relationships of VP-16 analogues |
| Q35706214 | Structure-based design, synthesis and biological testing of piperazine-linked bis-epipodophyllotoxin etoposide analogs |
| Q46371632 | Studies on DNA topoisomerase activity during in vitro chromatin assembly |
| Q37332317 | Substituents on etoposide that interact with human topoisomerase IIalpha in the binary enzyme-drug complex: contributions to etoposide binding and activity. |
| Q36934032 | Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells |
| Q40694338 | Teniposide: overview of its therapeutic potential in adult cancers |
| Q36685541 | The ascidian natural product eusynstyelamide B is a novel topoisomerase II poison that induces DNA damage and growth arrest in prostate and breast cancer cells |
| Q39658304 | The clinical pharmacology of etoposide and teniposide |
| Q36839637 | The geometry of DNA supercoils modulates topoisomerase-mediated DNA cleavage and enzyme response to anticancer drugs |
| Q33922870 | Topoisomerase II - drug interaction domains: identification of substituents on etoposide that interact with the enzyme. |
| Q36782421 | Topoisomerase II cleavage of herpes simplex virus type 1 DNA in vivo is replication dependent |
| Q40535267 | Topoisomerase II in multiple drug resistance |
| Q36920787 | Topoisomerase-specific drug sensitivity in relation to cell cycle progression |
| Q90643414 | Topoisomerases and cancer chemotherapy: recent advances and unanswered questions |
| Q37877829 | Topoisomerases, new targets in cancer chemotherapy |
| Q79685121 | Two cases of secondary acute myeloid leukemia accompanying adult T-cell leukemia/lymphoma |